Romiplostim: A New Approach for ITP?

A therapeutic protein that raises platelet counts, rather than prevents platelet destruction, could hold promise in treating this autoimmune disorder.

The goal of most therapies for immune thrombocytopenic purpura (ITP) is to reduce the rate of platelet destruction, but inadequate platelet production can also play a role in ITP. A recent study showed that stimulating thrombopoiesis with a thrombopoietin receptor agonist might be a useful therapeutic strategy (Journal Watch Dec 27 2007). Another thrombopoietin receptor agonist — romiplostim — is the subject of this report.

In two parallel studies that were funded and partially conducted by the manufacturer of romiplostim, investigators randomized 63 splenectomized and 62 nonsplenectomized patients with ITP and platelet counts lower than 30 cells/mm³ to receive weekly subcutaneous injections of romiplostim or placebo for 24 weeks. Doses were…

Reviewing Author

Bruce Soloway, MD

Disclosures

Editorial BoardsNew RoAR News (http://www.newroarnews.org)

Bruce Soloway, MD

Disclosures

Editorial BoardsNew RoAR News (http://www.newroarnews.org)